Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

被引：83

作者：

Fried, MW

Shiffman, ML

Reddy, RK

Smith, C

Marino, G

Goncales, F

Haeussinger, D

Diago, M

Carosi, G

Zarski, JP

Hoffman, J

Yu, J

机构：

[1] Univ N Carolina, Chapel Hill, NC 27515 USA

[2] Med Coll Virginia, Richmond, VA USA

[3] Univ Miami, Miami, FL 33152 USA

[4] Minnesota Clin Res Ctr, St Paul, MN USA

[5] Prince Wales Hosp, Randwick, NSW 2031, Australia

[6] Cidade Univ Zeferino Vaz, Campinas, Brazil

[7] Univ Dusseldorf, D-4000 Dusseldorf, Germany

[8] Hosp Gen Valencia, Valencia, Spain

[9] Univ Degli Study, Brescia, Italy

[10] Hosp Tronche, Grenoble, France

[11] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

来源：

关键词：

D O I：

10.1016/S0016-5085(01)80271-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

289

引用

页码：A55 / A55

页数：1